The risks of toxicity are significant in cancer chemotherapy when control of tumors is achieved by conventional methods and dosages of drug therapy. The present study was undertaken to develop a system for sustained, steady release of drugs from a depot supply within a polymer capsule. Capsules containing Cytoxan, FUDR, TEM and HN 2 were tested against lymphosarcoma tumor in hamsters. Subcutaneous implants of single 15 mm. capsules had little effect on tumor growth. Two 15 mm. capsules containing HN 2 were effective in decreasing tumor growth but resulted in toxicity. Interstitial or intratumor implants of 10 mm. capsules resulted in necrosis of tumor cells, increased fibrosis and vascularity of the tumors and decreased frequency rate of systemic metastases. There were no fatalities or drops in white blood cell counts. Intratumor capsule implants of HN 2 in adenocarcinoma tumor in hamsters resulted in an 80% decrease in the tumor size with no systemic toxicity. These preliminary studies suggest a potential usefulness of this new mode for administering anticancer drugs.
|Original language||English (US)|
|Number of pages||12|
|Journal||Review of surgery|
|State||Published - Dec 1 1973|
ASJC Scopus subject areas